The Complete 2023 Microbiome Landscape Review
An overview of the entire drug and trial landscape with a lens on disease indication, status and more, as well as a look at Deals and Companies data by deal type and company location and the future of the space.
About the report
The analysis contains:
-
- The Drug Landscape – An analysis of all 870+ assets in the Microbiome database by drug phase and status, disease indication and more, including a comparison of H1 and H2 of 2023.
- The Trial and Future Landscape – An analysis of the 640+ clinical trials tracked on Beacon Microbiome and a deeper look into trends within the space, including disease indications and investments.
- The Commercial Landscape – A look at deals in the commercial space by type and value along with a overview of the company data, including location and headcount, using the brand new Deals and Companies database. Along with a review of the regulatory announcements.
You may also be interested in...
H1 2024 Microbiome Landscape Review
Investment Trends in Early-Stage Biopharma: A Beacon Data Perspective
Microbiome: US Market and LBP Development
Find out more
Beacon is the essential decision-support tool for developers of complex therapeutics. Our market-defining, proprietary ontologies, combined with the most accurate and comprehensive life sciences data, provide our customers with unparalleled visibility of the drug and trial landscape.
With Beacon, you can make drug development decisions with confidence. This is why 23 of the world’s top 25 drug developers trust us.
Speak with our team
Our dedicated account and research teams can help you with questions by showing you how this insight and data is collated on Beacon.
